Steven M. Fruchtman, M.D., President and Chief Executive Officer, Onconova Therapeutics discusses Rigosertib, a drug that has the potential to downregulate the RAS pathway, the most commonly mutated gene in cancer. Rigosertib is a proprietary phase 3 small molecule, currently being evaluated in second-line treatment of patients with higher-risk myelodysplastic syndrome (MDS) and refractory higher-risk MDS patients. Also known as pre-leukemia, MDS is a cancer of the bone marrow stem cell and the mission of Onconova is to prolong the lives of those suffering from this disease.
@Onconova_ONTX
#cancer #oncology #RAS #MDS #PreLeukemia #Leukemia $ONTX
Onconova.com
Download the transcript here
Empowered Patient Podcast